Psoriasis Treatment Market to Surge at a CAGR over 10.2% over 2025 to 2032; Growing Psoriasis Cases Globally to Boost Market Growth

The global psoriasis treatment market size was valued at USD 27.20 billion in 2024. The market is projected to grow from USD 29.15 billion in 2025 to USD 57.68 billion by 2032, exhibiting a CAGR of 10.2% during the forecast period.

Fortune Business Insights™ presents this information in its report titled “Psoriasis Treatment Market Size, Share & Industry Analysis, By Drug Class (TNF Inhibitors, Interleukins Inhibitors, and Others), By Type (Plaque Psoriasis, Psoriatic Arthritis, and Others), By Product Type (Biologics and Non-Biologics), By Route of Administration (Oral, Parenteral/Systemic, and Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2025-2032”.

Psoriasis, characterized by autoimmune inflammation and excessive skin cell growth, presents as painful, itchy skin with redness and plaque formation. Companies are actively allocating resources toward the R&D of both biologic and non-biologic medications, with a focus on addressing the needs of adults who have active psoriatic arthritis. This ongoing commitment to innovation in treatment aims to introduce more efficacious therapeutic options, consequently fueling the growth of the psoriasis treatment sector.

The COVID-19 pandemic spurred market growth, driven by increased demand, key player revenues, and R&D investments in psoriasis treatment. Telemedicine witnessed a surge in psoriasis treatment, indicating higher success rates compared to conventional care, while projected innovations in therapies, including biologics, promise steady market growth.

Biocon Biologics Signed a License Agreement with Janssen Biotech Inc. and Johnson & Johnson to Commercialize Bmab 1200

Biocon Biologics revealed the signing of a settlement and license agreement with Janssen Biotech Inc. and Johnson & Johnson (collectively known as Janssen), enabling the commercialization of Bmab 1200, a proposed biosimilar to Stelara in the US. Stelara, endorsed for treating conditions such as psoriasis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis, achieved sales of USD 7 billion in the U.S in 2023.

Rising Prevalence of Psoriasis to Bolster Market Growth

The surge in psoriasis cases globally, including over eight million individuals in the U.S., as per National Psoriasis Foundation data published in 2023, fuels the demand for safe and efficient treatments, propelling psoriasis treatment market growth. Moreover, government and industry-led awareness campaigns, alongside the introduction of new drugs, bolster psoriasis treatment options and drive market growth in the foreseeable future.

However, the substantial expense associated with such treatments, including expensive topical medications and biologics, acts as a significant barrier to market growth.

Key Players are Focusing on Expanding Distribution Networks to Strengthen their Market Presence 

Johnson & Johnson Services, Inc. and AbbVie Inc. lead the competitive landscape of the market, supported by their robust global distribution networks. These players' focus on developing comprehensive treatments for all types of psoriasis enhances their stronghold in the industry.

List of Key Players Mentioned in the Report:

• AbbVie Inc. (U.S.)
• Novartis AG (Switzerland)
• Johnson & Johnson Services, Inc.(U.S.)
• Pfizer Inc. (U.S.)
• LEO Pharma A/S (Denmark)
• Merck & Co., Inc. (U.S.)
• Amgen Inc. (U.S.)
• Eli Lilly and Company (U.S.)
• Evelo Biosciences, Inc. (U.S.)
• UCB S.A. (Belgium)
• Sun Pharmaceutical Industries Ltd. (India)

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/psoriasis-treatment-market-100600

Key Industry Development:

• March 2023- The European Commission granted approval to Bristol Myers Squibb for Sotyktu, intended for the treatment of moderate-to-severe plaque psoriasis in adult patients.

Further Report Findings

• North America’s market size reached USD 20.32 billion in 2024. Government-led efforts to reform healthcare facilities in North America, aimed at enhancing medical accessibility, are fueling market expansion within the region.
• Government initiatives aimed at increasing awareness about the complications of prolonged psoriasis among the population in Asia Pacific are fueling market growth.
• In terms of product type, the market is classified into biologics and non-biologics. The biologics segment captured the key psoriasis treatment market share in 2023 and is touted to continue its market dominance during the forecast period. Biologics offer significant advantages for such treatments, such as shorter treatment durations, increased efficacy, targeted therapeutic approaches, and improved patient outcomes, solidifying the segment's growth trajectory.

Table of Segmentation